Insitu Biologics

What Insitu Biologics does

InSitu Biologics, Inc. is a privately held, near-clinical-stage life sciences company headquartered in Oakdale, Minnesota, developing a proprietary injectable sustained-release drug delivery platform. The company's core technology is a liquid formulation that transforms into a localized gel-like depot upon injection, enabling site-specific, controlled release of therapeutic agents over multiple days while minimizing systemic drug exposure. The platform is tunable and designed to support multiple therapeutic areas, with the company's stated intent to expand beyond the lead program into oncology and infection management.

The lead clinical product candidate, INSB200™, is a ropivacaine-based sustained-release peripheral nerve block (PNB) formulation intended for post-operative pain management. INSB200 is designed to deliver more than three days and up to five days of targeted analgesia from a single PNB injection, compared with the 8–24 hours of relief provided by standard ropivacaine or bupivacaine nerve blocks. Motor block is expected to resolve within 12–18 hours while analgesia extends up to five days, and the localized depot is designed to reduce cardiotoxicity versus standard local anesthetics. The product is being advanced under the FDA 505(b)(2) regulatory pathway, with IND submission planned for Q3 2026 and Phase 1/2 clinical trials in bunionectomy patients targeted for Q4 2026, with data readout anticipated in late 2027 or early 2028.

The business model is currently pre-commercial. The company has no approved product, no disclosed revenue, and no distribution channels. The intended go-to-market is an enterprise field sales motion targeting US hospitals, ambulatory surgery centers, and orthopedic practices performing high-pain surgical procedures, where the value proposition centers on reducing opioid reliance and the duration mismatch between short-acting local anesthetics and multi-day post-surgical pain. Capital is sourced through venture funding (approximately $10.9M disclosed across 2018, 2021, and 2025 rounds), and execution is supported by a CDMO partner (August Bio), a CRO partner (PRC Clinical), corporate counsel (Faegre Drinker), and IP counsel (Carlson Caspers).

Name

Insitu Biologics

Legal name

InSitu Biologics, Inc.

Website

https://insitubiologics.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

InSitu Biologics is a pre-revenue, near-clinical-stage life sciences company developing a proprietary injectable sustained-release drug delivery platform. Its lead candidate, INSB200, is a ropivacaine-based peripheral nerve block designed to deliver up to five days of post-operative pain relief from a single injection for hospitals, ambulatory surgery centers, and orthopedic practices.

Ownership category

akta.pro rank

Product category

Sustained-release injectable pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

akta.pro secondary industries

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Sustained-release drug delivery
• Post-operative pain management
• Peripheral nerve blocks
• Injectable pharmaceutical platform
• Local anesthetic formulations

Headquarters

HQ city

Minnesota City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Others

Revenue model

1. INSB200 Pharmaceutical Product Sales: Pre-revenue near-clinical-stage company. Planned revenue stream from commercialization of INSB200 as a sustained-release peripheral nerve block for post-operative pain management following regulatory approval.

Go-to-market motion1 record

Marketing channels1 record

Core offering

InSitu Biologics develops a proprietary tunable injectable sustained-release drug delivery platform. Its lead product candidate INSB200™ is a ropivacaine-based sustained-release peripheral nerve block (PNB) formulation that forms a localized depot at the injection site and elutes active pharmaceutical ingredient over 3-5 days, intended for post-operative pain management in high-pain surgical procedures such as bunionectomy. The company is advancing INSB200 through the FDA 505(b)(2) pathway with planned IND submission Q3 2026 and Phase 1/2 trial initiation Q4 2026.

Product overview

Insitu Biologics is a near-clinical-stage life sciences company advancing a proprietary tunable injectable platform for sustained-release drug delivery. The company's core product is INSB200™, a ropivacaine-based sustained-release peripheral nerve block designed for post-operative pain management. The platform technology enables controlled, localized delivery of therapeutic agents, with the potential to support future localized therapeutic programs across multiple therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

• INSB200™ A sustained-release ropivacaine-based local anesthetic for peripheral nerve blocks (PNB) designed to provide targeted post-operative pain relief for more than three days and up to five days from a single injection, while minimizing systemic drug exposure and reducing reliance on opioids. Intended for hospitals, ambulatory surgery centers, and orthopedic practices performing high-pain surgical procedures.
• Tunable Injectable Platform A proprietary injectable sustained-release drug delivery platform that enables site-specific delivery of therapeutic agents with tunable, controlled release profiles over multiple days, applicable to multiple therapeutic areas beyond pain management.

Quantifiable outcome

• Targeting more than 3 days and up to 5 days of localized analgesia from a single PNB injection
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and major.

• August BiocoreStrategic or Co-development PartnerContract development and manufacturing organization (CDMO) partner supporting formulation development and GMP production scalability for INSB200 and the proprietary platform technology.
• PRC ClinicalcoreImplementation/ SI/ Consulting PartnerContract research organization (CRO) providing personalized clinical trial services and advanced technologies to streamline clinical trial execution for INSB200 Phase 1/2 studies.
• Faegre DrinkermajorImplementation/ SI/ Consulting PartnerCorporate legal partner providing strategic guidance across corporate, transactional, and regulatory matters for the company.
• Carlson CaspersmajorImplementation/ SI/ Consulting PartnerIntellectual property counsel providing IP counseling and litigation services to safeguard innovation, assets, and growth.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Pfizer: Pfizer maintains a significant hospital and surgical anesthesia/analgesia portfolio (including postoperative pain products through its hospital business) and has historical M&A interest in non-opioid pain assets. It is a relevant incumbent comparable given its ability to commercialize INSB200-class assets globally.
• Johnson & Johnson (Janssen Pharmaceuticals): Janssen is a broad incumbent in the pain management and regional anesthesia market with multiple anesthetic and analgesic products and large-scale hospital/ASC commercial infrastructure. While not focused on a single long-acting injectable asset like INSB200, it represents the strategic commercialization benchmark and likely partnership/acquisition counterparty.

Direct peers

• Innocoll Pharmaceuticals: Innocoll has developed collagen-based sustained-release local anesthetic formulations (e.g., XARACOLL, POSIMIR assets historically) for postsurgical pain. Its focus on localized, extended-duration anesthetic delivery via biodegradable matrices makes it a comparable peer in the long-acting local anesthetic category.
• Camurus: Camurus commercializes the FluidCrystal (FLDepot) injectable depot technology for sustained-release drug delivery, including buprenorphine (Buvidal) and other long-acting injectables. Its depot-forming injectable platform is directly comparable to InSitu Biologics' tunable gel depot technology and shared focus on multi-day localized release.
• Durect Corporation: Durect developed POSIMIR, a sustained-release bupivacaine product for postsurgical pain via its SABER depot technology. Although POSIMIR had a difficult regulatory path, Durect's technology and approach to long-acting local anesthetics closely parallel InSitu Biologics' INSB200 sustained-release PNB platform.
• Heron Therapeutics: Heron developed ZYNRELEF, a long-acting fixed-dose combination of bupivacaine and meloxicam approved for surgical site infiltration in postsurgical pain. The company is a direct peer given its focus on extended-duration, non-opioid postsurgical pain management targeting the same providers and surgical settings as INSB200.
• Pacira BioSciences: Pacira is the leading developer and commercializer of long-acting local anesthetics, with EXPAREL (bupivacaine liposome injectable suspension) approved for postsurgical regional analgesia and PNB. It is the most direct competitive comparable to INSB200, with shared target indications (orthopedic and ambulatory surgery), shared customers (hospitals/ASCs), and an overlapping opioid-sparing value proposition.

Emerging players

• Taiwan Liposome Company (TLC Bio): TLC develops liposomal and nano-formulated sustained-release injectables, including TLC599 for osteoarthritis pain, sharing InSitu Biologics' focus on site-specific, long-acting injectable therapeutics for chronic and postsurgical pain indications.
• Adare Pharmaceuticals: Adare Pharma Solutions provides customized sustained-release and targeted delivery technologies, including for injectable and locally acting therapeutics. It overlaps with InSitu Biologics as a delivery-platform specialist serving pharmaceutical partners developing localized, extended-duration products.

Others

• Tarsus Pharmaceuticals: Tarsus is a late clinical-stage / early commercial specialty pharmaceutical company of comparable scale and stage, with similar reliance on a defined regulatory pathway and focused specialty indications. It is comparable as a benchmark for similarly sized US-based, privately funded specialty pharma companies, though its therapeutic focus (ophthalmology) is distinct.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/insitubiologics-inc
• Xx.com/InSituBiologics
• Facebookfacebook.com/insitubiologics

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Insitu Biologics